NASDAQ:TCRRTcr2 Therapeutics Stock Price, Forecast & News

$10.59

-0.95 (-8.23 %)

(As of 05/28/2020 02:33 PM ET)

Add

Compare

Today's Range

$10.55

Now: $10.59▼

$11.47

50-Day Range

$7.85

MA: $9.97▼

$11.37

52-Week Range

$5.84

Now: $10.59▼

$21.06

Volume8,279 shs

Average Volume91,432 shs

Market Capitalization$255.01 million

P/E RatioN/A

Dividend YieldN/A

Beta1.76

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Tcr2 Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.50, Tcr2 Therapeutics has a potential upside of 64.6% from its current price of $10.63.
Amount of Analyst Coverage
Tcr2 Therapeutics has only been the subject of 3 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Tcr2 Therapeutics has received 81 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Tcr2 Therapeutics has received 82 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Tcr2 Therapeutics has received 50.31% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Tcr2 Therapeutics and other stocks. Vote “Outperform” if you believe TCRR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TCRR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Tcr2 Therapeutics does not currently pay a dividend.
Dividend Growth
Tcr2 Therapeutics does not have a long track record of dividend growth.

2.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tcr2 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $482,467.00 in company stock.
Percentage Held by Insiders
39.07% of the stock of Tcr2 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
59.22% of the stock of Tcr2 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Tcr2 Therapeutics are expected to decrease in the coming year, from ($2.48) to ($2.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tcr2 Therapeutics is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tcr2 Therapeutics is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tcr2 Therapeutics has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.58 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TCRR

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.tcr2.com

Phone617-949-5200

Debt

Debt-to-Equity RatioN/A

Current Ratio21.69

Quick Ratio21.69

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$6.09 per share

Price / Book1.74

Profitability

EPS (Most Recent Fiscal Year)($4.62)

Net Income$-47,600,000.00

Net MarginsN/A

Return on Equity-32.20%

Return on Assets-30.77%

Miscellaneous

Employees47

Outstanding Shares24,080,000

Market Cap$255.01 million

Next Earnings Date8/13/2020 (Estimated)

OptionableNot Optionable

Receive TCRR News and Ratings via Email

Sign-up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter.

Tcr2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

How has Tcr2 Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Tcr2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TCRR stock has increased by 23.9% and is now trading at $10.63. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tcr2 Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tcr2 Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tcr2 Therapeutics.

When is Tcr2 Therapeutics' next earnings date?

Tcr2 Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tcr2 Therapeutics.

How were Tcr2 Therapeutics' earnings last quarter?

Tcr2 Therapeutics Inc (NASDAQ:TCRR) released its quarterly earnings results on Thursday, May, 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.05. View Tcr2 Therapeutics' earnings history.

What price target have analysts set for TCRR?

4 brokers have issued 12-month price targets for Tcr2 Therapeutics' stock. Their forecasts range from $16.00 to $19.00. On average, they anticipate Tcr2 Therapeutics' stock price to reach $17.50 in the next year. This suggests a possible upside of 64.6% from the stock's current price. View analysts' price targets for Tcr2 Therapeutics.

Has Tcr2 Therapeutics been receiving favorable news coverage?

Media headlines about TCRR stock have been trending very positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tcr2 Therapeutics earned a daily sentiment score of 3.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutTcr2 Therapeutics.

Are investors shorting Tcr2 Therapeutics?

Tcr2 Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 794,800 shares, a decline of 7.3% from the April 30th total of 857,200 shares. Based on an average trading volume of 84,200 shares, the days-to-cover ratio is presently 9.4 days. Currently, 6.5% of the shares of the company are short sold. View Tcr2 Therapeutics' Current Options Chain.

Who are some of Tcr2 Therapeutics' key competitors?

Some companies that are related to Tcr2 Therapeutics include Passage Bio (PASG), Sorrento Therapeutics (SRNE), Orchard Therapeutics (ORTX), Proteon Therapeutics (PRTO), Krystal Biotech (KRYS), Compugen (CGEN), Cellectis (CLLS), BioCryst Pharmaceuticals (BCRX), Replimune Group (REPL), Avrobio (AVRO), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), AVITA MED LTD/S (RCEL), Osiris Therapeutics (OSIR) and AVITA MED LTD/S (AVMXY). View all competitors.

What other stocks do shareholders of Tcr2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tcr2 Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Harpoon Therapeutics (HARP), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), Stoke Therapeutics (STOK) and Akero Therapeutics (AKRO).

Who are Tcr2 Therapeutics' key executives?

Tcr2 Therapeutics' management team includes the following people:

Dr. Garry E. Menzel, Pres, CEO & Director (Age 55)
Mr. Robert Hofmeister, Chief Scientific Officer (Age 52)
Dr. Alfonso Quintas Cardama M.D., Chief Medical Officer (Age 48)
Mr. Mayur Amrat Somaiya, Chief Financial Officer (Age 46)

When did Tcr2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering on Thursday, February 14th 2019. The company issued 5,000,000 shares at a price of $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is Tcr2 Therapeutics' stock symbol?

Tcr2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are Tcr2 Therapeutics' major shareholders?

Tcr2 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (7.34%), ArrowMark Colorado Holdings LLC (5.66%), BlackRock Inc. (3.71%), JPMorgan Chase & Co. (0.94%), Geode Capital Management LLC (0.80%) and Victory Capital Management Inc. (0.35%). Company insiders that own Tcr2 Therapeutics stock include Morana Jovan-Embiricos, Neil W Gibson and Upnorth Investment Ltd. View institutional ownership trends for Tcr2 Therapeutics.

Which institutional investors are selling Tcr2 Therapeutics stock?

TCRR stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Morgan Stanley, UBS Group AG, First Trust Advisors LP, Victory Capital Management Inc., and Victory Capital Management Inc.. Company insiders that have sold Tcr2 Therapeutics company stock in the last year include Morana Jovan-Embiricos, and Neil W Gibson. View insider buying and selling activity for Tcr2 Therapeutics.

Which institutional investors are buying Tcr2 Therapeutics stock?

TCRR stock was purchased by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, DAFNA Capital Management LLC, Soleus Capital Management L.P., IndexIQ Advisors LLC, JPMorgan Chase & Co., Geode Capital Management LLC, Parametric Portfolio Associates LLC, and BlackRock Inc.. Company insiders that have bought Tcr2 Therapeutics stock in the last two years include Morana Jovan-Embiricos, and Upnorth Investment Ltd. View insider buying and selling activity for Tcr2 Therapeutics.

How do I buy shares of Tcr2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tcr2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $10.63.

How big of a company is Tcr2 Therapeutics?

Tcr2 Therapeutics has a market capitalization of $255.97 million. The company earns $-47,600,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis. Tcr2 Therapeutics employs 47 workers across the globe.

What is Tcr2 Therapeutics' official website?

The official website for Tcr2 Therapeutics is www.tcr2.com.

How can I contact Tcr2 Therapeutics?

Tcr2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff